According to the latest disclosure from the U.S. Securities and Exchange Commission, trading of Lyra Therapeutics Inc (stock code: LYRA) shares will be officially suspended at the market open on March 17, 2026.

This major decision has been officially announced through regulatory documents, marking a critical turning point for the biotechnology company's capital markets. Trading suspension usually indicates that the company is facing significant corporate actions or regulatory scrutiny. For Lyra Therapeutics, which focuses on developing novel otology therapies, this suspension may involve deep factors such as strategic restructuring, merger and acquisition transactions, or adjustments to its financial structure. Investors should closely monitor subsequent announcements to obtain clear information regarding equity structure, business direction, or potential delisting procedures.